Visceral leishmaniasis
MONDO:0005445A severe form of leishmaniasis characterized by irregular bouts of fever, substantial weight loss, swelling of the spleen and liver, and anemia (which may be serious). If left untreated it may lead to death. Two species of Leishmania are known to give rise to the visceral form of the disease. The species commonly found in East Africa and the Indian subcontinent is L. donovani and the species found in Europe, North Africa, and Latin America is L. infantum, also known as L. chagasi.
Also known as: kala-azar, viscus leishmaniasis, kala-azar susceptibility, kala-azar, susceptibility to
37 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New hope against a deadly parasitic disease: LXE408 shows promise in phase II trial
Disease control CompletedThis study tested a new drug called LXE408 in 101 adults and teens with visceral leishmaniasis, a serious parasitic disease. Participants received one of two LXE408 doses or a standard treatment. The goal was to see if LXE408 could clear the parasite and improve symptoms by day 2…
Phase: PHASE2 • Sponsor: Drugs for Neglected Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Old drug, new hope? ivermectin tackles stubborn skin disease
Disease control CompletedThis early study tested whether the drug ivermectin could safely treat post-kala-azar dermal leishmaniasis (PKDL), a skin condition that can appear after recovery from visceral leishmaniasis. Ten otherwise healthy adults with PKDL took ivermectin pills for five days each month fo…
Phase: EARLY_PHASE1 • Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope against a deadly parasite: LXE408 trial shows promise
Disease control CompletedThis study tested a new drug called LXE408 in 52 adults with visceral leishmaniasis, a serious parasitic disease. The goal was to see if LXE408 could cure the infection by Day 28 compared to the standard treatment. The trial took place in Ethiopia and measured safety, drug levels…
Phase: PHASE2 • Sponsor: Drugs for Neglected Diseases • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Rural patients get Hospital-Level care at home in landmark trial
Disease control CompletedThis study looked at whether giving hospital-level care to acutely ill adults in their own homes in rural areas works well. 160 people with various conditions like infections, heart failure, or COPD took part. The goal was to see if this approach could lower costs and help patien…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Old drug, new hope? ivermectin tested for stubborn skin disease
Disease control CompletedThis early study tested whether the common anti-parasite drug ivermectin could treat post-kala-azar dermal leishmaniasis (PKDL), a skin condition that can spread a serious disease. Thirty people in Bangladesh received either ivermectin pills for 3 months or the standard drug milt…
Phase: EARLY_PHASE1 • Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh • Aim: Disease control
Last updated Jun 26, 2026 16:42 UTC
-
New rapid test for infection and inflammation put to the test
Diagnosis CompletedThis study looked at how well a new, quick finger-prick test (LumiraDx CRP) measures CRP levels compared to a standard lab test. CRP is a marker of infection, inflammation, or tissue injury. 79 adults with symptoms of these conditions took part. The goal was to see if the new tes…
Sponsor: LumiraDx UK Limited • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New PET scan technique aims to sniff out hidden infections
Diagnosis CompletedThis early study tested whether a special PET scan using a radioactive form of vitamin B9 (11C-PABA) can help doctors see infections deep inside the body. Researchers scanned 13 healthy people and patients with known or suspected infections. The goal was to see if this method can…
Sponsor: Johns Hopkins University • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
New biosensors aim to diagnose infections in minutes
Diagnosis CompletedThis study tested two new types of biosensor platforms to detect viruses, bacteria, and parasites in blood and respiratory samples. The goal was to see if these devices could be accurate, fast, and cheap alternatives to standard lab tests. Researchers enrolled 149 adults with or …
Sponsor: University of Bologna • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
Generic antifungal drug shows promise in early comparison study
Knowledge-focused CompletedThis study compared a new generic version of liposomal amphotericin B (an antifungal drug) to the brand-name version (AmBisome®) in 58 healthy Chinese adults. Each volunteer received a single dose of both drugs at different times to see if the generic works the same way in the bo…
Phase: NA • Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Generic antifungal drug put to the test in healthy volunteers
Knowledge-focused CompletedThis study checked if a new version of the antifungal drug amphotericin B liposome works the same as the original. 42 healthy adults received a single dose of each version at different times. The goal was to see if the drug levels in the blood were similar enough to consider the …
Phase: NA • Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
ICU antibiotic dosing: what really matters?
Knowledge-focused CompletedThis study looked at 156 critically ill patients to find out what factors help achieve the right levels of beta-lactam antibiotics in the blood. Researchers collected clinical data and used therapeutic drug monitoring to see which patients reached target concentrations. The goal …
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC